Note 7 • Research and Development
|
€’000 |
2010 |
2009 |
|
Research and development |
11,341 |
10,780 |
- Start page
- Introduction
- This is Oriflame
- Operational Excellence
- Financials
- Directors report
- Consolidated statements
- Consolidated income statements
- Consolidated statements of cash flows
- Consolidated statements of changes in equity
- Consolidated statements of comprehensive income
- Consolidated statements of financial position
- Report of the reviseur d’entreprises agree
- Financial notes
- Note 1: Status and principal activity
- Note 2: Basis of preparation and summary of significant accounting policies
- Note 3: Segment reporting
- Note 4: Other income
- Note 5: Employee benefit expense
- Note 6: Auditor’s remuneration
- Note 7: Research and development
- Note 8: Depreciation and amortisation
- Note 9: Financial income and expense
- Note 10: Income tax expense
- Note 11: Earnings per share
- Note 12: Property, plant and equipment
- Note 13: Intangible assets
- Note 14: Investment property
- Note 15: Deferred taxation
- Note 16: Inventories
- Note 17: Trade and other receivables
- Note 18: Cash and cash equivalents net of bank overdraft
- Note 19: Share capital
- Note 20: Reserves
- Note 21: Interest-bearing loans
- Note 22: Trade and other payables
- Note 23: Equity compensation plans
- Note 24: Related parties
- Note 25: Group companies
- Note 26: Provisions, commitments and contingent liabilities
- Note 27: Pensions
- Note 28: Financial instruments and financial risk management
- Note 29: Restructuring and impairment Iran
- Board of directors
Financial Note 7 • Research and Development | Oriflame Annual Report 2010
Oriflame Annual Report 2010